Somatostatin versus cimetidine in the treatment of actively bleeding duodenal ulcer: a prospective, randomized, controlled trial.

Abstract

In a double-blind, prospective, randomized trial, the healing effect of somatostatin was compared with that of cimetidine in 67 patients with endoscopically confirmed duodenal ulcer with active bleeding (33 patients were treated with somatostatin, 34 with cimetidine). Intravenous infusion of either drug was administered for 48 or 72 h. Somatostatin had a higher rate of control of bleeding (30 vs. 24 patients at 72 h; p less than 0.05) and had less mean transfusion requirements (4.4 vs. 5.8 units; p less than 0.01). Need for surgical intervention and the mortality figures show a trend in favor of somatostatin. There was no difference in rebleeding rate.

• Authors: Z Tulassay, R Gupta, J Papp, A Bodnár
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 84 Issue 1 Pg. 6-9 (Jan 1989) ISSN: 0002-9270 [Print] United States
• PMID: 2563190 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Somatostatin
• Cimetidine

Topics

• Aged
• Cimetidine (therapeutic use)
• Duodenal Ulcer (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Peptic Ulcer Hemorrhage (drug therapy, surgery)
• Prospective Studies
• Random Allocation
• Recurrence
• Somatostatin (therapeutic use)